Peter Rasmussen
Comptroller/Controller/Auditor bei ASCENDIS PHARMA A/S
Vermögen: 53 540 $ am 30.04.2024
Aktive Positionen von Peter Rasmussen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ASCENDIS PHARMA A/S | Comptroller/Controller/Auditor | 01.03.2014 | - |
Finanzdirektor/CFO | 01.02.2016 | 01.08.2016 |
Karriereverlauf von Peter Rasmussen
Ehemalige bekannte Positionen von Peter Rasmussen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AdvanDx, Inc.
AdvanDx, Inc. Medical SpecialtiesHealth Technology AdvanDx, Inc. provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. Its products include QuickFISH BC Tests, PNA FISH Tests, ASR PNA Probes, starter system, accessories and package inserts. The firm offers diagnostic solutions that include antimicrobial stewardship, blood culture contamination, staphylococcal bacteremia, enterococcal bacteremia, gram-negative bacteremia and candidemia. The company was founded by Henrik Stender and Thais T. Johansen in 2002 and is headquartered in Woburn, MA. | Finanzdirektor/CFO | 01.06.2008 | 01.08.2012 |
VELOXIS PHARMACEUTICALS A/S | Finanzdirektor/CFO | 01.01.2007 | 01.01.2008 |
Ausbildung von Peter Rasmussen
Copenhagen Business School | Graduate Degree |
Statistik
International
Dänemark | 4 |
Vereinigte Staaten | 2 |
Operativ
Director of Finance/CFO | 3 |
Graduate Degree | 1 |
Comptroller/Controller/Auditor | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ASCENDIS PHARMA A/S | Health Technology |
Private Unternehmen | 2 |
---|---|
AdvanDx, Inc.
AdvanDx, Inc. Medical SpecialtiesHealth Technology AdvanDx, Inc. provides advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. Its products include QuickFISH BC Tests, PNA FISH Tests, ASR PNA Probes, starter system, accessories and package inserts. The firm offers diagnostic solutions that include antimicrobial stewardship, blood culture contamination, staphylococcal bacteremia, enterococcal bacteremia, gram-negative bacteremia and candidemia. The company was founded by Henrik Stender and Thais T. Johansen in 2002 and is headquartered in Woburn, MA. | Health Technology |
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Börse
- Insiders
- Peter Rasmussen
- Erfahrung